Lipigon Pharmaceuticals AB (publ) (STO:LPGO)
Sweden
· Delayed Price · Currency is SEK 0.0029
-0.0003 (-9.38%)
Apr 29, 2026, 4:44 PM CET
STO:LPGO Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | - | 10.29 | 16.41 | - | 2.21 | Upgrade
|
| Revenue Growth (YoY) | - | -37.30% | - | - | -44.86% | Upgrade
|
| Cost of Revenue | 22.84 | 28.7 | 21.52 | 31.66 | 38.25 | Upgrade
|
| Gross Profit | -22.84 | -18.41 | -5.12 | -31.66 | -36.04 | Upgrade
|
| Selling, General & Admin | 8.85 | 7.81 | 7.44 | 6.07 | 5.44 | Upgrade
|
| Other Operating Expenses | 0.53 | 0.64 | 0.87 | 0.39 | 0.69 | Upgrade
|
| Operating Expenses | 9.46 | 8.51 | 8.33 | 6.48 | 6.12 | Upgrade
|
| Operating Income | -32.29 | -26.93 | -13.45 | -38.13 | -42.16 | Upgrade
|
| Interest Expense | -0.22 | -0.06 | -0 | - | -0.01 | Upgrade
|
| Interest & Investment Income | - | 0.38 | 0.25 | 0.04 | 0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.07 | 1.35 | 1.07 | 0.39 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | 0 | - | 0.97 | Upgrade
|
| EBT Excluding Unusual Items | -32.44 | -25.26 | -12.13 | -37.71 | -41.11 | Upgrade
|
| Pretax Income | -32.44 | -25.26 | -12.13 | -37.71 | -41.11 | Upgrade
|
| Net Income | -32.44 | -25.26 | -12.13 | -37.71 | -41.11 | Upgrade
|
| Net Income to Common | -32.44 | -25.26 | -12.13 | -37.71 | -41.11 | Upgrade
|
| Shares Outstanding (Basic) | 404 | 138 | 64 | 15 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 404 | 138 | 64 | 15 | 9 | Upgrade
|
| Shares Change (YoY) | 191.76% | 115.86% | 336.30% | 63.10% | 104.09% | Upgrade
|
| EPS (Basic) | -0.08 | -0.18 | -0.19 | -2.57 | -4.56 | Upgrade
|
| EPS (Diluted) | -0.08 | -0.18 | -0.19 | -2.57 | -4.56 | Upgrade
|
| Free Cash Flow | -35.88 | -25.02 | -14.32 | -37.47 | -35.42 | Upgrade
|
| Free Cash Flow Per Share | -0.09 | -0.18 | -0.22 | -2.55 | -3.93 | Upgrade
|
| Gross Margin | - | -179.00% | -31.19% | - | - | Upgrade
|
| Operating Margin | - | -261.74% | -81.95% | - | -1906.83% | Upgrade
|
| Profit Margin | - | -245.59% | -73.92% | - | -1859.48% | Upgrade
|
| Free Cash Flow Margin | - | -243.18% | -87.27% | - | -1601.94% | Upgrade
|
| EBITDA | -32.21 | -26.87 | -13.42 | -38.11 | -42.14 | Upgrade
|
| EBITDA Margin | - | -261.16% | -81.81% | - | - | Upgrade
|
| D&A For EBITDA | 0.08 | 0.06 | 0.02 | 0.02 | 0.02 | Upgrade
|
| EBIT | -32.29 | -26.93 | -13.45 | -38.13 | -42.16 | Upgrade
|
| EBIT Margin | - | -261.74% | -81.95% | - | - | Upgrade
|
| Revenue as Reported | 0.07 | 11.64 | 17.48 | 0.39 | 3.18 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.